Gastro-oesophageal complications in patients receiving cancer therapy: The role of proton pump inhibitors

European Journal of Gastroenterology and Hepatology

Volumn 14, Issue SUPPL. 1, 2002, Pages

  Steer, Christopher B ^a   Harper, Peter G ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Corticosteroid; Histamine type 2 receptor antagonist; Irradiation; Mucositis; Proton pump inhibitor; Ulcer

Indexed keywords

ANTIEMETIC AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIULCER AGENT; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DEXAMETHASONE; ETOPOSIDE; FLUOROURACIL; HISTAMINE H2 RECEPTOR ANTAGONIST; IFOSFAMIDE; LANSOPRAZOLE; METHOTREXATE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PENTAGASTRIN; PLACEBO; PROSTAGLANDIN E1 DERIVATIVE; PROTECTIVE AGENT; PROTON PUMP INHIBITOR; RANITIDINE; STEROID; SUCRALFATE;

BREAST CARCINOMA; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; COLON CARCINOMA; CONFERENCE PAPER; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM ULCER; DUODENUM PERFORATION; DUODENUM ULCER; ESOPHAGUS INJURY; GASTROINTESTINAL MUCOSA; HUMAN; MUCOSA INFLAMMATION; PEPTIC ULCER; PRIORITY JOURNAL; RADIATION INJURY; STOMACH MUCOSA INJURY; STOMACH PERFORATION; STOMACH ULCER; UPPER GASTROINTESTINAL TRACT;

ADRENAL CORTEX HORMONES; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; GASTROINTESTINAL DISEASES; HUMANS; INTESTINAL MUCOSA; PROTON PUMPS; RADIATION INJURIES; RADIOTHERAPY; WOUND HEALING;

EID: 0036748783     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Clarkson JE, Worthington HV, Eden OB. Prevention of oral mucositis or oral candidiasis for patients with cancer receiving chemotherapy (excluding head and neck cancer). Cochrane Database Syst Rev 2000; 2:CD000978.
2. Werner-Wasik M, Pequignot E, Leeper D, Hauck W, Curran W Jr. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys 2000; 48:689-696.
3. Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys 2000; 47:1-12.
4. Kennedy L, Diamond J. Assessment and management of chemotherapy-induced mucositis in children. J Pediatr Oncol Nurs 1997; 14:164-174.
5. Spijkervet FK, Sonis ST. New frontiers in the management of chemotherapy-induced mucositis. Curr Opin Oncol 1998; 10(Suppl. 1):S23-S27.
6. Blijlevens NMA, Donnelly JP, De Pauw BE. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant 2000; 25:1269-1278.
7. Sartori S, Nielsen I, Maestri A, Beltrami D, Trevisani L, Pazzi P. Acute gastroduodenal mucosal injury after cisplatin plus etoposide chemotherapy: clinical and endoscopic study. Oncology 1991; 48:356-361.
8. Donnelly JP, Muus P, Schattenberg A, De Witte T, Horrevorts A, De Pauw BE. A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients. Bone Marrow Transplant 1992; 9:409-413.
9. Levy J. The effects of antibiotic use on gastrointestinal function. Am J Gastroenterol 2000; 95(Suppl.):S8-S10.
10. Podolsky DK. Healing the epithelium: solving the problem from two sides. J Gastroenterol 1997; 32:122-126.
11. Sartori S, Trevisani L, Nielsen I, Tassinari D, Panzini I, Abbasciano V. Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury. J Clin Oncol 2000; 18:463-467.
12. Jewel LD, Fields AC, Murray CJ, Thomson AB. Erosive gastroduodenitis with marked epithelial atypia after hepatic arterial infusion chemotherapy. Am J Gastroenterol 1985; 80:421-424.
13. 1 analogue. Gastroenterology 1987; 92:566-569.
14. Franzen L, Henriksson R, Littbrand B, Zackrisson B. Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region: a double-blind placebo-controlled study. Acta Oncol 1995; 34:219-223.
15. Shield MJ. Novel applications of misoprostol. Pharmacol Ther 1995; 65:125-147.
16. Dueñas-Gonzalez A, Sobrevilla-Calvo P, Frias-Mendivil M, Gallardo-Rincon D, Lara-Medina F, Aguilar-Ponce L, et al. Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. Bone Marrow Transplantation 1996; 17:809-812.
17. Slavin RE, Dias MA, Saral R. Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols: a clinical-pathologic study of 33 patients. Cancer 1978; 42:1747-1759.
18. Sartori S, Trevisani L, Nielsen I, Tassinari D, Abbasciano V. Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury: a randomized, placebo-controlled pilot study. Cancer 1996; 78:1477-1482.
19. Koop H, Koop I, Klein M, Stumpf M, Massarrat S, Arnold R. Irradiation-induced duodenal ulcer disease refractory to ranitidine: healing by omeprazole. J Clin Gastroenterol 1989; 11:631-634.
20. Twycross R. The risks and benefits of corticosteroids in advanced cancer. Drug Safety 1994; 11:163-178.
21. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994; 236:619-632.
22. Messer J, Reitman D, Sacks HS, Smith H Jr, Chalmers TC. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983; 309:21-24.
23. Liaw C-C, Huang J-S, Wang H-M, Wang C-H. Spontaneous gastroduodenal perforation in patients with cancer receiving chemotherapy and steroids: report of four cases combining 5-fluorouracil infusion and cisplatin with antiemetics dexamethasone. Cancer 1993; 72:1382-1385.
24. Kuwayama H, Matsuo Y, Eastwood GL. Effects of sucralfate, lansoprazole, and cimetidine on the delayed healing by hydrocortisone sodium phosphate of chronic gastric ulcers in the rat. Am J Med 1991; 91(Suppl. 2A): 15S-19S.